兴齐眼药(300573) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was CNY 301,958,988.82, representing a 45.73% increase compared to CNY 207,199,852.20 in the same period last year[3] - Net profit attributable to shareholders for Q1 2022 was CNY 74,168,573.48, a significant increase of 123.36% from CNY 33,206,280.03 in the previous year[3] - The net cash flow from operating activities reached CNY 103,314,893.79, up 118.32% from CNY 47,323,461.01 in the same period last year[3] - The company reported a basic earnings per share of CNY 0.84, which is a 110.00% increase compared to CNY 0.40 in the previous year[3] - The total operating revenue for the first quarter was 301,958,988.82 CNY, an increase of 45.6% compared to 207,199,852.20 CNY in the same period last year[22] - The net profit for the first quarter of 2022 was CNY 74,168,573.48, a 97.6% increase compared to CNY 37,543,286.84 in the same period last year[23] - Operating profit reached CNY 87,958,734.62, up 110.8% from CNY 41,711,645.63 year-on-year[23] - Revenue from sales of goods and services amounted to CNY 313,334,689.40, compared to CNY 213,664,991.62 in the previous year, reflecting a growth of 46.7%[25] - Total comprehensive income for the period was CNY 74,168,573.48, compared to CNY 37,543,286.84 in the same quarter last year, marking a significant increase[24] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,683,347,867.31, a slight decrease of 0.21% from CNY 1,686,844,280.72 at the end of the previous year[3] - The total assets amounted to 1,683,347,867.31 CNY, slightly down from 1,686,844,280.72 CNY at the beginning of the year[21] - The total liabilities decreased to 259,956,416.46 CNY from 342,351,345.70 CNY, a reduction of 24.1%[21] Cash Flow - The net cash flow from investing activities was CNY -52,486,090.96, reflecting a 175.28% increase in cash outflows for fixed asset purchases[8] - The company repaid bank loans, resulting in a cash flow from financing activities of CNY -102,567,434.93, a decrease of 658.39% compared to the previous year[8] - The cash and cash equivalents at the end of the period were 634,657,660.68 CNY, down from 686,360,276.14 CNY at the beginning of the year, a decrease of 7.5%[19] - The company incurred a total of CNY 122,567,434.93 in cash outflows from financing activities, compared to CNY 61,631,596.98 in the previous year[27] Research and Development - The company's R&D expenses increased by 37.58% due to higher clinical trial costs during the reporting period[6] - Research and development expenses increased to CNY 22,312,058.34, up from CNY 20,024,595.26, indicating a focus on innovation[23] Shareholder Information - The company issued 5,763,282 A-shares at a price of RMB 104.05 per share, raising a total of RMB 599,669,492.10, with a net amount of RMB 580,179,086.77 after deducting issuance costs[15] - The registered capital increased from RMB 82.33 million to RMB 88.10 million following the issuance of new shares[15] - The company reported a total of 20,879,325 restricted shares at the beginning of the period, with 5,772,449 shares remaining restricted at the end of the period[14] - The company has 18,881,625 restricted shares held by executive Liu Jidong, which are subject to a 25% annual unlock[12] - The company has a total of 468,000 restricted shares for other incentive plan participants, which remain locked[14] - The company has 961,076 shares held by Citic Lyon Asset Management, which are also subject to lock-up[13] - The company has not disclosed any related party relationships among its top shareholders[11] Corporate Developments - The company received the High-tech Enterprise Certificate, allowing it to enjoy a reduced corporate income tax rate of 15% for three years[18] - The company appointed a new non-independent director, Li Chunhua, following the resignation of Liu Gaozhi[17] Operating Costs - The total operating costs for the first quarter were 214,113,341.19 CNY, up from 166,430,260.09 CNY, reflecting a year-over-year increase of 28.7%[22] - The accounts receivable increased to 111,705,036.16 CNY from 108,148,643.62 CNY, showing a growth of 2.4%[19] - The inventory balance rose to 105,139,260.39 CNY, compared to 92,330,953.24 CNY at the start of the year, indicating an increase of 14.0%[19] Audit Information - The company did not conduct an audit for the first quarter report[28]